Abstract:
|
Alzheimer's drug trials have historically suffered fairly high failure rates. The ability of early study results to predict trial success or failure is an interesting issue facing industry and regulatory agencies. In this talk, we will share what we have learned through building the FDA Integrative Alzheimer's Trial Database. We will briefly discuss the process of building the Database, and then whether an early detection signal can be found based on what we have learned in the process of building the Database. Initial findings suggest that cognitive measurements might be better than global measurements in predicting the trial success.
|